US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ATS Corp.

19.36

+0.18000.94%

Volume:72.68K

Turnover:1.41M

Market Cap:1.90B

PE:57.58

High:19.51

Open:19.51

Low:19.29

Close:19.18

52wk High:35.82

52wk Low:18.41

Shares:98.13M

Float Shares:74.29M

Volume Ratio:0.44

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.3362

EPS(LYR):0.5242

ROE:2.69%

ROA:2.92%

PB:1.48

PE(LYR):36.93

Loading ...

Overview Company News Filings

Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Press Release: ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern

Press Release: Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Calendar of U.S. Earnings Expected in the Week Ahead

RBC Capital Keeps Their Buy Rating on ATS Corporation (ATS)

Australis Oil & Gas launches market-linked long term incentive plan for employees

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Entravision’s Earnings Call: ATS Fuels Profitable Turnaround

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Australis Oil & Gas Wins Strong Shareholder Backing at AGM

Press Release: Securitize Receives Approval to Enable Custody and Atomic Settlement for Tokenized Securities

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Vicore Pharma to Spotlight Buloxibutid Data at 2026 ATS Meeting

Press Release: PureTech Announces Annual Results for Year Ended December 31, 2025

ATS Corporation price target raised to C$51 from C$48 at Scotiabank

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/ATS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","market":"US","secType":"STK","nameCN":"ATS Corp.","latestPrice":19.36,"timestamp":1789661427034,"preClose":19.18,"halted":0,"volume":72678,"delay":0,"changeRate":0.009384775808133457,"floatShares":74294500,"shares":98126900,"eps":0.336239,"marketStatus":"Trading","change":0.18,"latestTime":"09-17 12:11:01 EDT","open":19.51,"high":19.51,"low":19.29,"amount":1409140.0058580001,"amplitude":0.01147,"askPrice":19.36,"askSize":53,"bidPrice":19.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.336239,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"listingDate":1684987200000,"exchange":"NYSE","adjPreClose":19.18,"preHourTrading":{"tag":"盘前","latestPrice":18.9,"preClose":19.18,"latestTime":"09:26 EDT","volume":201,"amount":3799.68993,"timestamp":1789651605462,"change":-0.28,"changeRate":-0.014599,"amplitude":0.041189},"postHourTrading":{"tag":"盘后","latestPrice":19.17,"preClose":19.18,"latestTime":"19:30 EDT","volume":9223,"amount":177010.78496,"timestamp":1789601404640,"change":-0.01,"changeRate":-0.000521,"amplitude":0.000521},"volumeRatio":0.439312,"impliedVol":0.5365,"impliedVolPercentile":0.8127},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","floatShares":74294500,"roa":"2.92%","roe":"2.69%","lyrEps":0.524235,"volumeRatio":0.439312,"shares":98126900,"dividePrice":0,"high":19.51,"amplitude":0.01147,"preClose":19.18,"low":19.29,"week52Low":18.41,"pbRate":"1.48","psRate":"0.91","week52High":35.82,"institutionHeld":0,"latestPrice":19.36,"committee":0.30719,"eps":0.336239,"divideRate":0,"volume":72678,"delay":0,"ttmEps":0.336239,"open":19.51,"prevYearClose":27.54,"prevWeekClose":19.2,"prevMonthClose":19.26,"prevQuarterClose":28.78,"fiveDayClose":19.03,"twentyDayClose":19.77,"sixtyDayClose":27.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"ATS","fiscalQuarterEnding":"2026/06","expectedEps":0.28,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2026-05-28","symbol":"ATS","fiscalQuarterEnding":"2026/03","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1779940800000,"reportTimeType":"pre","actualEps":0.26},{"market":"US","date":"2026-02-04","symbol":"ATS","fiscalQuarterEnding":"2025/12","expectedEps":0.3,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770181200000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2025-11-05","symbol":"ATS","fiscalQuarterEnding":"2025/09","expectedEps":0.31,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":0.33},{"market":"US","date":"2025-08-07","symbol":"ATS","fiscalQuarterEnding":"2025/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0,"sell":1,"strongSell":0,"meanLabel":"SELL","meanPercent":1,"analysts":1,"updateTime":1771473600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATS","date":"2026-09-16","current":57.578092,"percent":0.865,"low":-897.033197,"twenty":-92.214508,"median":33.45372,"eighty":48.434351,"high":254.533797,"avg":-30.975766,"sd":237.712525,"marketCap":1856547158.94},"quantilePoints":[{"date":"2023-06-02","current":46.343344,"twenty":46.194425,"median":46.266425,"eighty":46.306886,"marketCap":4385290976.46},{"date":"2023-06-09","current":46.009827,"twenty":46.17581,"median":46.28258,"eighty":46.915752,"marketCap":4390539453.8},{"date":"2023-06-16","current":45.438012,"twenty":45.320112,"median":46.164952,"eighty":46.476751,"marketCap":4375388926.84},{"date":"2023-06-23","current":48.145057,"twenty":45.487654,"median":46.266425,"eighty":47.860268,"marketCap":4658766213.85},{"date":"2023-06-30","current":46.896248,"twenty":45.651659,"median":46.266425,"eighty":47.485058,"marketCap":4511580364.18},{"date":"2023-07-07","current":46.270844,"twenty":46.009827,"median":46.312962,"eighty":47.5378,"marketCap":4411747145.22},{"date":"2023-07-14","current":48.698172,"twenty":46.043025,"median":46.511353,"eighty":47.780498,"marketCap":4728914205.59},{"date":"2023-07-21","current":48.480908,"twenty":46.105078,"median":46.872979,"eighty":48.286922,"marketCap":4686318579.71},{"date":"2023-07-28","current":45.850462,"twenty":46.043025,"median":46.851428,"eighty":48.286922,"marketCap":4428020690.86},{"date":"2023-08-04","current":44.368411,"twenty":46.009827,"median":46.763285,"eighty":48.152813,"marketCap":4237745227.85},{"date":"2023-08-11","current":42.700705,"twenty":45.438012,"median":46.511353,"eighty":48.145057,"marketCap":4326916372.16},{"date":"2023-08-18","current":40.050115,"twenty":44.926078,"median":46.32649,"eighty":48.075247,"marketCap":4021626143.41},{"date":"2023-08-25","current":41.899702,"twenty":43.443089,"median":46.270844,"eighty":48.061899,"marketCap":4194356348.69},{"date":"2023-08-31","current":43.312379,"twenty":42.678859,"median":46.219245,"eighty":47.836778,"marketCap":4344740041.37},{"date":"2023-09-08","current":43.843953,"twenty":42.897314,"median":46.105078,"eighty":47.634879,"marketCap":4353234860.78},{"date":"2023-09-15","current":43.042951,"twenty":42.657014,"median":45.930144,"eighty":47.433983,"marketCap":4325894000.62},{"date":"2023-09-22","current":41.921548,"twenty":42.559437,"median":45.562117,"eighty":47.311701,"marketCap":4220969734.92},{"date":"2023-09-29","current":42.533222,"twenty":42.508464,"median":45.081733,"eighty":47.274981,"marketCap":4280367687.17},{"date":"2023-10-06","current":40.050115,"twenty":42.428364,"median":44.926078,"eighty":47.160162,"marketCap":3958860964.51},{"date":"2023-10-13","current":39.423877,"twenty":42.00893,"median":44.615828,"eighty":47.035061,"marketCap":3917634187.34},{"date":"2023-10-20","current":36.088795,"twenty":41.126371,"median":44.229891,"eighty":46.935301,"marketCap":3572025991.12},{"date":"2023-10-27","current":34.661554,"twenty":40.778231,"median":44.058847,"eighty":46.909266,"marketCap":3403618402.31},{"date":"2023-11-03","current":33.358105,"twenty":40.050115,"median":43.843953,"eighty":46.860392,"marketCap":3284508208.07},{"date":"2023-11-10","current":31.05346,"twenty":39.978754,"median":43.47968,"eighty":46.850053,"marketCap":3541182846.54},{"date":"2023-11-17","current":33.712074,"twenty":39.645245,"median":43.312379,"eighty":46.711431,"marketCap":3845894896.75},{"date":"2023-11-24","current":33.592349,"twenty":38.190334,"median":43.072078,"eighty":46.623309,"marketCap":3848769791.51},{"date":"2023-12-01","current":33.655362,"twenty":35.166914,"median":42.886392,"eighty":46.541855,"marketCap":3891785593.98},{"date":"2023-12-08","current":33.604952,"twenty":34.322082,"median":42.591477,"eighty":46.44537,"marketCap":3879525100.59},{"date":"2023-12-15","current":35.923838,"twenty":34.218738,"median":42.507736,"eighty":46.366559,"marketCap":4204253502},{"date":"2023-12-22","current":36.07507,"twenty":34.272496,"median":42.474968,"eighty":46.323119,"marketCap":4257700834.69},{"date":"2023-12-29","current":36.289315,"twenty":34.310293,"median":42.423994,"eighty":46.304224,"marketCap":4315633982.44},{"date":"2024-01-05","current":34.650971,"twenty":34.327977,"median":42.161849,"eighty":46.287991,"marketCap":4072504954.25},{"date":"2024-01-12","current":35.442932,"twenty":34.397952,"median":41.910625,"eighty":46.273191,"marketCap":4139113955.77},{"date":"2024-01-19","current":36.274955,"twenty":34.423844,"median":41.655761,"eighty":46.2585,"marketCap":4216951441.35},{"date":"2024-01-26","current":36.917882,"twenty":34.562753,"median":40.778299,"eighty":46.231655,"marketCap":4292072985.19},{"date":"2024-02-02","current":36.987217,"twenty":34.654752,"median":40.235802,"eighty":46.154093,"marketCap":4330447033.68},{"date":"2024-02-09","current":31.2472,"twenty":34.423844,"median":40.050115,"eighty":46.10731,"marketCap":4053209917.9},{"date":"2024-02-16","current":29.911027,"twenty":34.218738,"median":40.010065,"eighty":46.067846,"marketCap":3869003534.07},{"date":"2024-02-23","current":28.569192,"twenty":34.062459,"median":39.908119,"eighty":46.029746,"marketCap":3697982548.6},{"date":"2024-03-01","current":28.954191,"twenty":33.729718,"median":39.700587,"eighty":45.946081,"marketCap":3727658474.68},{"date":"2024-03-08","current":28.897573,"twenty":33.622723,"median":38.630157,"eighty":45.760452,"marketCap":3749905081.21},{"date":"2024-03-15","current":28.33706,"twenty":33.535637,"median":37.535596,"eighty":45.60011,"marketCap":3663186667.6},{"date":"2024-03-22","current":28.378306,"twenty":33.360741,"median":37.125888,"eighty":45.512475,"marketCap":3664397837.7},{"date":"2024-03-28","current":27.463826,"twenty":33.187804,"median":36.956482,"eighty":45.379062,"marketCap":3545999564.77},{"date":"2024-04-05","current":25.261057,"twenty":31.829239,"median":36.880063,"eighty":45.11865,"marketCap":3270651387.12},{"date":"2024-04-12","current":24.173756,"twenty":30.404732,"median":36.432536,"eighty":45.004481,"marketCap":3078077137.88},{"date":"2024-04-19","current":24.609778,"twenty":29.677763,"median":36.289315,"eighty":44.938488,"marketCap":3127556802.58},{"date":"2024-04-26","current":25.396884,"twenty":29.011941,"median":36.169269,"eighty":44.868397,"marketCap":3239367008.29},{"date":"2024-05-03","current":25.125077,"twenty":28.84322,"median":36.062467,"eighty":44.633305,"marketCap":3203669221.23},{"date":"2024-05-10","current":26.025435,"twenty":28.633736,"median":35.997283,"eighty":44.566345,"marketCap":3323128791.91},{"date":"2024-05-17","current":23.786609,"twenty":28.457413,"median":35.841921,"eighty":44.342163,"marketCap":3384597470.53},{"date":"2024-05-24","current":21.936652,"twenty":28.195987,"median":35.701363,"eighty":44.23426,"marketCap":3102092113.2},{"date":"2024-05-31","current":21.435159,"twenty":27.970637,"median":35.598334,"eighty":44.222609,"marketCap":3039383806.02},{"date":"2024-06-07","current":22.690097,"twenty":27.463826,"median":35.382456,"eighty":43.895086,"marketCap":3211638521.11},{"date":"2024-06-14","current":22.285278,"twenty":26.048085,"median":35.173981,"eighty":43.895086,"marketCap":3139567043.35},{"date":"2024-06-21","current":21.323834,"twenty":25.875989,"median":34.8436,"eighty":43.864406,"marketCap":3015344623.92},{"date":"2024-06-28","current":22.482628,"twenty":25.849972,"median":34.751792,"eighty":43.843953,"marketCap":3180274284.27},{"date":"2024-07-05","current":21.972427,"twenty":25.639244,"median":34.657272,"eighty":43.651713,"marketCap":3127376247.29},{"date":"2024-07-12","current":22.998515,"twenty":25.494281,"median":34.422199,"eighty":43.533747,"marketCap":3270585876.4},{"date":"2024-07-15","current":22.953023,"twenty":25.430859,"median":34.413972,"eighty":43.516271,"marketCap":3254489261.98},{"date":"2024-08-02","current":20.309458,"twenty":25.403679,"median":34.373922,"eighty":43.501635,"marketCap":2841766295.19},{"date":"2024-08-09","current":20.723514,"twenty":25.129607,"median":34.224644,"eighty":43.440249,"marketCap":2735666122.5},{"date":"2024-08-16","current":19.860035,"twenty":24.796645,"median":34.162619,"eighty":43.405587,"marketCap":2630022203.9},{"date":"2024-08-23","current":19.838448,"twenty":24.268888,"median":33.920018,"eighty":43.283252,"marketCap":2645505418.49},{"date":"2024-08-30","current":19.471469,"twenty":23.8321,"median":33.734128,"eighty":43.147809,"marketCap":2621186477.04},{"date":"2024-09-06","current":18.602592,"twenty":23.494241,"median":33.671115,"eighty":43.072078,"marketCap":2495925620.93},{"date":"2024-09-13","current":19.185441,"twenty":22.907687,"median":33.604952,"eighty":43.042951,"marketCap":2560815499.76},{"date":"2024-09-20","current":20.831449,"twenty":22.803751,"median":33.570295,"eighty":43.028387,"marketCap":2786196948.41},{"date":"2024-09-27","current":21.948725,"twenty":22.594145,"median":33.45372,"eighty":42.744396,"marketCap":2956487278.6},{"date":"2024-10-04","current":21.646505,"twenty":22.472834,"median":33.3614,"eighty":42.700705,"marketCap":2900362552.24},{"date":"2024-10-11","current":21.560157,"twenty":22.285278,"median":33.233174,"eighty":42.591477,"marketCap":2843647655.11},{"date":"2024-10-18","current":22.617927,"twenty":22.261739,"median":32.698187,"eighty":42.533222,"marketCap":2977792893.11},{"date":"2024-10-25","current":22.645897,"twenty":22.285278,"median":31.73976,"eighty":42.511377,"marketCap":2967565955.08},{"date":"2024-10-31","current":23.088453,"twenty":22.329808,"median":31.05346,"eighty":42.505551,"marketCap":3006452868.32},{"date":"2024-11-08","current":30.478219,"twenty":22.389519,"median":30.568298,"eighty":42.486619,"marketCap":2853731574.85},{"date":"2024-11-15","current":30.530988,"twenty":22.401664,"median":30.478219,"eighty":42.476424,"marketCap":2830133907.78},{"date":"2024-11-22","current":30.757144,"twenty":22.402758,"median":30.568681,"eighty":42.451666,"marketCap":2862659955.58},{"date":"2024-11-29","current":33.961013,"twenty":22.434826,"median":30.673837,"eighty":42.419625,"marketCap":3148783777.17},{"date":"2024-12-06","current":34.669633,"twenty":22.46611,"median":30.907914,"eighty":42.257969,"marketCap":3210086264.85},{"date":"2024-12-13","current":33.207161,"twenty":22.47871,"median":31.108842,"eighty":42.148741,"marketCap":3040755582.89},{"date":"2024-12-20","current":31.48838,"twenty":22.488641,"median":31.48838,"eighty":42.00893,"marketCap":2849502272.41},{"date":"2024-12-27","current":33.734858,"twenty":22.494713,"median":31.970845,"eighty":41.91281,"marketCap":3041459063.87},{"date":"2025-01-03","current":33.410701,"twenty":22.507997,"median":32.326091,"eighty":41.867662,"marketCap":3006099952.21},{"date":"2025-01-10","current":30.583758,"twenty":22.548751,"median":32.187154,"eighty":41.739502,"marketCap":2758779888.76},{"date":"2025-01-17","current":28.714206,"twenty":22.594145,"median":31.76484,"eighty":41.57202,"marketCap":2591110278.91},{"date":"2025-01-24","current":30.922991,"twenty":22.613171,"median":31.446918,"eighty":40.977822,"marketCap":2794075415.08},{"date":"2025-01-31","current":29.754521,"twenty":22.627085,"median":31.164224,"eighty":40.788494,"marketCap":2682414705.78},{"date":"2025-02-07","current":44.52783,"twenty":22.642592,"median":31.108842,"eighty":40.977822,"marketCap":2778433490.84},{"date":"2025-02-14","current":46.096561,"twenty":22.681257,"median":31.405456,"eighty":41.965239,"marketCap":2894690862.79},{"date":"2025-02-21","current":45.29574,"twenty":22.741461,"median":31.73976,"eighty":42.419625,"marketCap":2847627453.27},{"date":"2025-02-28","current":46.79865,"twenty":22.792532,"median":32.079,"eighty":42.507008,"marketCap":2895255396.7},{"date":"2025-03-07","current":41.862084,"twenty":22.806185,"median":32.332694,"eighty":42.635168,"marketCap":2622361985.36},{"date":"2025-03-14","current":41.423278,"twenty":22.822194,"median":32.713389,"eighty":42.635168,"marketCap":2565848922.04},{"date":"2025-03-21","current":43.880591,"twenty":22.853037,"median":32.981006,"eighty":43.034213,"marketCap":2732813300.12},{"date":"2025-03-28","current":42.224099,"twenty":22.88278,"median":33.123373,"eighty":43.054602,"marketCap":2633489494.72},{"date":"2025-04-04","current":39.042756,"twenty":22.901877,"median":33.222238,"eighty":43.034213,"marketCap":2482102274.67},{"date":"2025-04-11","current":36.168577,"twenty":22.907687,"median":33.258379,"eighty":42.953904,"marketCap":2303349084},{"date":"2025-04-17","current":36.662234,"twenty":22.91307,"median":33.3614,"eighty":42.840307,"marketCap":2360722684.91},{"date":"2025-04-25","current":38.011562,"twenty":22.933896,"median":33.415912,"eighty":42.72692,"marketCap":2443342344.25},{"date":"2025-05-02","current":38.318726,"twenty":22.957542,"median":33.501164,"eighty":42.694361,"marketCap":2471450690},{"date":"2025-05-09","current":38.494248,"twenty":22.972956,"median":33.554541,"eighty":42.647498,"marketCap":2471983722.75},{"date":"2025-05-16","current":42.432532,"twenty":22.990951,"median":33.59865,"eighty":42.694361,"marketCap":2705638771.71},{"date":"2025-05-23","current":39.240219,"twenty":23.03449,"median":33.649379,"eighty":42.706785,"marketCap":2525720011.68},{"date":"2025-05-30","current":-145.081888,"twenty":22.98843,"median":33.649379,"eighty":42.736874,"marketCap":2948051518.8},{"date":"2025-06-06","current":-141.392185,"twenty":22.910379,"median":33.59865,"eighty":42.706785,"marketCap":2905577142.42},{"date":"2025-06-13","current":-147.065973,"twenty":22.838868,"median":33.554541,"eighty":42.705569,"marketCap":3029340885.66},{"date":"2025-06-20","current":-147.588101,"twenty":22.775703,"median":33.508702,"eighty":42.700705,"marketCap":3013637808.62},{"date":"2025-06-27","current":-151.382229,"twenty":22.617927,"median":33.434816,"eighty":42.684845,"marketCap":3112877198.05},{"date":"2025-07-03","current":-154.340953,"twenty":22.496776,"median":33.387698,"eighty":42.610151,"marketCap":3191028919.77},{"date":"2025-07-11","current":-140.452356,"twenty":22.445425,"median":33.283584,"eighty":42.544873,"marketCap":2878692397.63},{"date":"2025-07-18","current":-148.841207,"twenty":22.329808,"median":33.214699,"eighty":42.515746,"marketCap":3036782441.3},{"date":"2025-07-25","current":-150.163931,"twenty":22.224904,"median":33.070283,"eighty":42.505551,"marketCap":3090657544.76},{"date":"2025-08-01","current":-146.369803,"twenty":21.983688,"median":33.000575,"eighty":42.486619,"marketCap":2966528128.91},{"date":"2025-08-08","current":-101.054949,"twenty":21.94631,"median":32.80762,"eighty":42.476424,"marketCap":2880442495.37},{"date":"2025-08-15","current":-97.518773,"twenty":21.761929,"median":32.336463,"eighty":42.451666,"marketCap":2771168115.02},{"date":"2025-08-22","current":-92.314119,"twenty":21.629235,"median":32.187154,"eighty":42.435194,"marketCap":2605351661.45},{"date":"2025-08-29","current":-94.430844,"twenty":21.416942,"median":31.76484,"eighty":42.408226,"marketCap":2690809366.58},{"date":"2025-09-05","current":-94.231623,"twenty":21.21908,"median":31.446918,"eighty":42.295319,"marketCap":2669825633.28},{"date":"2025-09-12","current":-95.028508,"twenty":20.931914,"median":31.164224,"eighty":42.186749,"marketCap":2693629533.12},{"date":"2025-09-19","current":-96.921109,"twenty":20.265687,"median":30.941837,"eighty":42.148741,"marketCap":2753845197.92},{"date":"2025-09-26","current":-91.367818,"twenty":19.971207,"median":30.757144,"eighty":42.098311,"marketCap":2572349952.97},{"date":"2025-10-03","current":-91.467429,"twenty":19.836289,"median":30.673837,"eighty":41.981136,"marketCap":2565172507.46},{"date":"2025-10-10","current":-91.890774,"twenty":19.770448,"median":30.583758,"eighty":41.90844,"marketCap":2570628933.63},{"date":"2025-10-17","current":-92.538243,"twenty":19.536178,"median":30.429218,"eighty":41.877131,"marketCap":2583489123.67},{"date":"2025-10-24","current":-94.057305,"twenty":19.426136,"median":30.327448,"eighty":41.829173,"marketCap":2635618172.4},{"date":"2025-10-31","current":-92.861977,"twenty":19.191917,"median":30.172909,"eighty":41.766594,"marketCap":2604412516.09},{"date":"2025-11-07","current":-840.478534,"twenty":18.877826,"median":30.012938,"eighty":41.639013,"marketCap":2763562438.19},{"date":"2025-11-14","current":-794.27753,"twenty":-24.454255,"median":29.885544,"eighty":41.482775,"marketCap":2634611431.77},{"date":"2025-11-21","current":-720.44031,"twenty":-90.690466,"median":29.754521,"eighty":41.357457,"marketCap":2378964442.77},{"date":"2025-11-28","current":-749.131344,"twenty":-91.427585,"median":29.66191,"eighty":41.252143,"marketCap":2481656418.02},{"date":"2025-12-05","current":-772.548291,"twenty":-92.025248,"median":29.434134,"eighty":41.138054,"marketCap":2574939374.84},{"date":"2025-12-12","current":-806.302449,"twenty":-92.468515,"median":29.33919,"eighty":40.994795,"marketCap":2719740619.47},{"date":"2025-12-19","current":-802.71607,"twenty":-92.687659,"median":29.038708,"eighty":40.808883,"marketCap":2711086457.01},{"date":"2025-12-26","current":-818.116404,"twenty":-92.881899,"median":28.925882,"eighty":40.778231,"marketCap":2780190128.31},{"date":"2026-01-02","current":-797.652946,"twenty":-93.036296,"median":28.85511,"eighty":40.777958,"marketCap":2701366821.38},{"date":"2026-01-09","current":-829.523643,"twenty":-93.982597,"median":28.79,"eighty":40.732159,"marketCap":2780572966.83},{"date":"2026-01-16","current":-897.033197,"twenty":-94.20672,"median":28.721744,"eighty":40.421489,"marketCap":3000957491.22},{"date":"2026-01-23","current":-852.94102,"twenty":-94.306331,"median":28.652131,"eighty":40.345308,"marketCap":2872825063.23},{"date":"2026-01-30","current":-822.139786,"twenty":-94.500572,"median":28.625809,"eighty":40.26483,"marketCap":2822985227.98},{"date":"2026-02-06","current":208.384924,"twenty":-94.699793,"median":28.600331,"eighty":40.345308,"marketCap":2876417798.07},{"date":"2026-02-13","current":217.783795,"twenty":-94.679871,"median":28.638821,"eighty":40.788494,"marketCap":3016893475.65},{"date":"2026-02-20","current":231.284936,"twenty":-94.545397,"median":28.714206,"eighty":41.221427,"marketCap":3190649761.48},{"date":"2026-02-27","current":231.233009,"twenty":-94.440805,"median":28.789796,"eighty":41.766594,"marketCap":3191752106.95},{"date":"2026-03-06","current":221.5745,"twenty":-94.430844,"median":28.835294,"eighty":41.981136,"marketCap":3051363607.19},{"date":"2026-03-13","current":200.855441,"twenty":-94.356136,"median":28.925882,"eighty":42.295319,"marketCap":2784391762.71},{"date":"2026-03-20","current":221.5745,"twenty":-94.306331,"median":29.083593,"eighty":42.477881,"marketCap":3051096603.42},{"date":"2026-03-27","current":212.798758,"twenty":-94.261506,"median":29.339504,"eighty":42.556524,"marketCap":2902003820.96},{"date":"2026-04-02","current":208.384924,"twenty":-94.231623,"median":29.434134,"eighty":42.704353,"marketCap":2827964511.21},{"date":"2026-04-10","current":220.172459,"twenty":-94.221662,"median":29.66191,"eighty":42.891084,"marketCap":3007447997.08},{"date":"2026-04-17","current":223.288107,"twenty":-94.186798,"median":29.795983,"eighty":43.045296,"marketCap":3074984579.03},{"date":"2026-04-24","current":242.189704,"twenty":-94.117071,"median":29.911027,"eighty":43.246201,"marketCap":3342818367},{"date":"2026-05-01","current":228.844345,"twenty":-94.057305,"median":30.049577,"eighty":43.475217,"marketCap":3174723129.99},{"date":"2026-05-08","current":246.272749,"twenty":-94.027422,"median":30.199294,"eighty":43.611845,"marketCap":3409841478.72},{"date":"2026-05-15","current":231.205429,"twenty":-93.952714,"median":30.334384,"eighty":43.895086,"marketCap":3179217752.6},{"date":"2026-05-22","current":235.985407,"twenty":-93.748512,"median":30.478219,"eighty":44.315916,"marketCap":3232400113.88},{"date":"2026-05-29","current":57.523315,"twenty":-93.439719,"median":30.583758,"eighty":44.536606,"marketCap":2984982176.15},{"date":"2026-06-05","current":53.770604,"twenty":-93.135906,"median":30.673837,"eighty":44.890309,"marketCap":2770878710.36},{"date":"2026-06-12","current":51.072486,"twenty":-93.021354,"median":30.757144,"eighty":44.999546,"marketCap":2612540227.64},{"date":"2026-06-18","current":54.770414,"twenty":-92.961588,"median":30.922991,"eighty":45.218949,"marketCap":2776051661.63},{"date":"2026-06-26","current":54.729326,"twenty":-92.961588,"median":31.108842,"eighty":45.537083,"marketCap":2762476455.87},{"date":"2026-07-02","current":55.98936,"twenty":-92.901822,"median":31.326328,"eighty":45.76965,"marketCap":2827451643.92},{"date":"2026-07-10","current":53.811692,"twenty":-92.866958,"median":31.73976,"eighty":46.016467,"marketCap":2721009214.95},{"date":"2026-07-17","current":53.551467,"twenty":-92.822133,"median":32.079,"eighty":46.098264,"marketCap":2732558690.37},{"date":"2026-07-24","current":51.017702,"twenty":-92.752406,"median":32.332694,"eighty":46.164576,"marketCap":2593422796.68},{"date":"2026-07-31","current":51.414887,"twenty":-92.662756,"median":32.619157,"eighty":46.2585,"marketCap":2628572436.16},{"date":"2026-08-07","current":58.956307,"twenty":-92.598009,"median":32.916928,"eighty":46.323119,"marketCap":1983485975},{"date":"2026-08-14","current":57.723341,"twenty":-92.573107,"median":33.048853,"eighty":46.623309,"marketCap":1954834878.45},{"date":"2026-08-21","current":54.764224,"twenty":-92.548204,"median":33.191812,"eighty":46.869356,"marketCap":1877081843.92},{"date":"2026-08-28","current":55.175212,"twenty":-92.433652,"median":33.233174,"eighty":47.274981,"marketCap":1879054542.77},{"date":"2026-09-04","current":55.524552,"twenty":-92.334041,"median":33.3614,"eighty":47.893058,"marketCap":1901224013.26},{"date":"2026-09-11","current":54.16829,"twenty":-92.274275,"median":33.413307,"eighty":48.149711,"marketCap":1850663349.86},{"date":"2026-09-16","current":54.805322,"twenty":-92.214508,"median":33.45372,"eighty":48.434351,"marketCap":1856547158.94}],"updateTime":1789661461345},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635899440","title":"Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899440","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899440?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Randomized Phase 2 trial initiated for agenT-797 in severe acute lung. injury and respiratory distress, with preliminary data expected in the. -- AACR and ASGCT presentations showcase durable survival and. context-dependent iNKT activity in cancer and inflammatory lung disease. -- Non-dilutive collaborations expand MiNK's platform and potentiate. meaningful commercial revenue potential, while preserving focus on lead. Dr. Buell continued, \"What continues to distinguish agenT-797 is both its biology and its practicality. As an off-the-shelf iNKT cell therapy administered without lymphodepletion or HLA matching, agenT-797 is designed for settings where immune dysfunction drives poor outcomes and where speed, tolerability and deployability matter. We believe this is particularly relevant in severe acute lung injury and critical illness, where patients often face a cascade of respiratory failure, secondary infection and organ dysfunction with limited therapeutic options.\". MiNK initiate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","INKT","ATS","BK4139","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086190","title":"Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086190","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086190?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842800,"startTime":"0","endTime":"0","summary":"Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295720/0/en/Kymera-Therapeutics-Announces-Presentations-on-KT-621-a-First-In-Class-Oral-STAT6-Degrader-at-the-Society-for-Investigative-Dermatology-and-American-Thoracic-Society-Congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BP","LU0541502299.USD","BK4115","BPH","LU0072461881.USD","LU1829250122.USD","ATS","BK4201","LU0300736062.USD","PN","KT","LU1162221912.USD","SG9999004220.SGD","LU0541501648.USD","BK4585","BK4117","LU0300736492.USD","BK4096","BK4006","LU0006061336.USD","AD","LU0162691827.USD","AFG","LU0320765646.SGD","BK4132","BK4588","BK4107","SID","KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721862","title":"Press Release: ATS to Host Fourth Quarter Earnings Call Thursday May 28, 2026, at 8:30 a.m. Eastern","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721862?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:23","pubTimestamp":1778793780,"startTime":"0","endTime":"0","summary":"ATS Corporation    will report its financial results for the fourth quarter ended March 31, 2026, before markets open on Thursday May 28, 2026.A replay of the conference will be available on the ATS website following the call. Alternatively, a telephone recording of the call will be available for one week  by dialing  770-2030 and entering passcode 8782510.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","ATS","EML"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635372501","title":"Press Release: Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635372501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635372501?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:30","pubTimestamp":1778790600,"startTime":"0","endTime":"0","summary":"TORONTO, May 14, 2026  -- Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2026 and provided an update on its business.During the second quarter, Edesa continued preparations for an upcoming Phase 2 clinical study of its drug candidate, EB06 , in moderate-to-severe nonsegmental vitiligo patients. The company reported that it has contracted a clinical research organization and initiated outreach to potential clinical sites and investigators. Based on this progress, Edesa reaffirmed its previous guidance that site activations and patient recruitment are expected to begin midyear 2026, subject to regulatory approval. For its respiratory program, the company also announced during the quarter additional positive data from its Phase 3 study of paridiprubart in subjects with Acute Respiratory Distress Syndrome. Most no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4161","BK4588","EDSA","XBI","ATS","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785056","title":"Press Release: Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785056","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635785056?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:00","pubTimestamp":1778670000,"startTime":"0","endTime":"0","summary":"-- Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP --. -- End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 --. \"We continue to make strong progress advancing our clinical programs in severe asthma and CRSwNP to position verekitug as a uniquely differentiated treatment option for these diseases,\" said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio. \"We are working diligently to deliver best-in-class efficacy with convenient quarterly at-home dosing, a profile that we believe will advance the standard of care for patients and maximize the potential commercial value of verekitug. We are continuing to prepare for our End-of-Phase 2 meetings with the FDA, which we expect to occur in mid-2026, and we remain on track to initiate Phase 3 dosing in both severe asthma and CRSwNP in the first quarter of 2027.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","TSLP","BK4139","ATS","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635000172","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635000172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635000172?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Copa Hldgs A                                     1Q      4.14    4:30 PM. ·FLEX LNG Ltd                                    1Q       .36    1:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABEO","AKA","AMAT","ATAT","ATYR","BZAI","CAAP","BEAT","CLBT","AUTL","BBWI","KARO","BTBT","ATS","BN","BTGO","CSWC","AVAH","BOOT","CMPS","PHVS","CCCC","CLPT","BIRK","CNTB","BGSI","AYTU","ALT","BHST","GOOS","AEBI","ARX","CELC","PYPD","CCAP","BWAY","CING","BLSH","BTDR","CSCO","BEEM","CSIQ","AQST","CPA","ALLO","DERM","CLNN","CBUS","ACOG","BABA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634496465","title":"RBC Capital Keeps Their Buy Rating on ATS Corporation (ATS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634496465","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634496465?lang=en_us&edition=fundamental","pubTime":"2026-05-09 09:54","pubTimestamp":1778291662,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Sabahat Khan from RBC Capital maintained a Buy rating on ATS Corporation, with a price target of C$51.00. According...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-ats-corporation-ats-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-ats-corporation-ats-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633439685","title":"Australis Oil & Gas launches market-linked long term incentive plan for employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2633439685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633439685?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:20","pubTimestamp":1778232039,"startTime":"0","endTime":"0","summary":"An update from Australis Oil & Gas ( ($AU:ATS) ) is now available. Australis Oil & Gas has outlined a new employee long term incentive program for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-launches-market-linked-long-term-incentive-plan-for-employees?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-launches-market-linked-long-term-incentive-plan-for-employees?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633714767","title":"Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633714767","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633714767?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:44","pubTimestamp":1778157840,"startTime":"0","endTime":"0","summary":"20+ presentations highlight expanding role in pediatric lung disease, treatment-response assessment, and pharma trial endpoints. Xenon MRI continues to evolve into a practical cardiopulmonary biomarker platform for clinical trials and therapeutic development","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290044/0/en/Xenon-MRI-Advances-as-a-Cardiopulmonary-Biomarker-Platform-at-ATS-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145553","title":"Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145553","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145553?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289806/0/en/Beam-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4556","BK4611","LU1861559042.SGD","BK4539","LENZ","BK4007","BK4505","BK4585","SCD","LU1861558580.USD","BK4588","BK4535","BK4139","BEAM","IND","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633976345","title":"Entravision’s Earnings Call: ATS Fuels Profitable Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2633976345","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633976345?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:15","pubTimestamp":1778026548,"startTime":"0","endTime":"0","summary":"Entravision Communications Corporation Class A (($EVC)) has held its Q1 earnings call. Read on for the main highlights of the call. Entravision Com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entravisions-earnings-call-ats-fuels-profitable-turnaround?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entravisions-earnings-call-ats-fuels-profitable-turnaround?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVC","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924297","title":"Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924297?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011500,"startTime":"0","endTime":"0","summary":"Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and contin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288254/0/en/Trevi-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","RCC","LABU","BK4007","BK4585","BK4588","BK4539","BK4139","LENZ","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925289","title":"Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925289","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925289?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:01","pubTimestamp":1778011260,"startTime":"0","endTime":"0","summary":"BOSTON, May  05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288206/0/en/Avalyn-to-Present-Patient-Centered-Research-on-AP01-Delivery-and-Supportive-Care-Experiences-at-American-Thoracic-Society-2026-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","BK4107","ATS","BK4161","AFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633300999","title":"Australis Oil & Gas Wins Strong Shareholder Backing at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633300999","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633300999?lang=en_us&edition=fundamental","pubTime":"2026-05-05 12:52","pubTimestamp":1777956733,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Australis Oil & Gas ( ($AU:ATS) ). Australis Oil & Gas shareholders endorsed all resolutions at the company’s A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-wins-strong-shareholder-backing-at-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-wins-strong-shareholder-backing-at-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","ATS","BK4161","BK4229","AGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955667","title":"Press Release: Securitize Receives Approval to Enable Custody and Atomic Settlement for Tokenized Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955667?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":"Becomes the First to Offer Full Stack Onchain IPO Infrastructure. The expanded approval was just granted through FINRA's Continuing Membership Application  process, which is required for broker-dealers to introduce new business lines or material capabilities. Through this process, Securitize Markets is now the first company to be approved to custody tokenized securities in a regular broker-dealer, enabling it to facilitate atomic swaps and clear and settle transactions between tokenized securities and stablecoins onchain. The approval also permits Securitize Markets to be an underwriter and selling group participant for both initial and secondary tokenized securities offerings.This milestone represents a major advancement for regulated digital asset markets, unlocking real-time, onchain settlement within a fully regulated broker-dealer framework and enhances Securitize's trading and distribution capabilities for tokenized securities.Securitize, the world's leader in tokenizing real-wor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4211","BK4585","CMA","TSS","BK4207","ATS","BK4588","BK4589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632722666","title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632722666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632722666?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579500,"startTime":"0","endTime":"0","summary":"Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3285477/0/en/Trevi-Therapeutics-Announces-Oral-Presentation-and-Multiple-Posters-Accepted-at-the-American-Thoracic-Society-ATS-2026-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","FAS","BK4585","BK4007","BK4139","BK4161","BK4107","BK4539","ATS","BK4117","BK4588","AFG","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","BK4201","LU0006061336.USD","RA","LU1162221912.USD","BP","IBD","AD","BK4006","BK4096","BK4132","LU1829250122.USD","SID","BK4588","ATS","PN","BPH","LU0072461881.USD","BK4139","KYMR","BK4585","BK4161","EASI","LU0162691827.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631569266","title":"Vicore Pharma to Spotlight Buloxibutid Data at 2026 ATS Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631569266","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631569266?lang=en_us&edition=fundamental","pubTime":"2026-04-29 14:57","pubTimestamp":1777445844,"startTime":"0","endTime":"0","summary":"Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma will showcase a series of new clinical and preclinical data on...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-to-spotlight-buloxibutid-data-at-2026-ats-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vicore-pharma-to-spotlight-buloxibutid-data-at-2026-ats-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823039010.USD","LU0979878070.USD","SG9999006266.SGD","SG9999002414.USD","SG9999002620.SGD","LU0210637038.USD","SG9999004360.SGD","LU2065170008.USD","BK4220","LU0441851309.USD","LU0737861269.HKD","LU0289960550.SGD","LU0516423091.SGD","LU0348788117.USD","LU0589944569.HKD","LU2543165471.USD","SG9999013460.SGD","LU0572940350.SGD","LU2125910500.SGD","BK4588","SG9999001135.SGD","LU1770036033.HKD","SG9999014484.SGD","SGXZ58947870.SGD","BK4503","LU2238330802.EUR","LU1048588211.SGD","LU2065171311.SGD","LU0345775950.USD","LU2125910849.SGD","LU2177674079.SGD","LU0516422366.SGD","LU0175139822.USD","BK4554","LU0823038988.USD","SG9999002679.SGD","LU1242518931.SGD","SG9999013486.USD","LU2360107671.USD","BK4585","SG9999013478.USD","LU1861217088.USD","ATS","BK4551","LU0264606111.USD","LU0532188223.SGD","LU0516422440.USD","LU0345776255.USD","BK4566","SG9999002604.SGD","LU2065169927.USD","IE0001KFT4U8.USD","LU0499858602.USD","SG9999014492.USD","SG9999005177.SGD","IE0031814969.USD","LU0261945553.USD","SG9999002406.SGD","LU2008162690.USD","LU0572939691.SGD","LU2065171402.SGD","BK4161","LU0499858438.USD","BK4581","LU0516422952.EUR","IE0034224299.USD","LU0048573645.USD","LU1242518857.USD","LU2045819591.USD","BK4535","BK4085","LU1839390173.USD","LU0516423174.USD","LU1861220207.SGD","LU0072462343.USD","IE00BD6J9T35.USD","LU2152927971.USD","LU0251143029.SGD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631367565","title":"Press Release: PureTech Announces Annual Results for Year Ended December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2631367565","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631367565?lang=en_us&edition=fundamental","pubTime":"2026-04-29 14:01","pubTimestamp":1777442460,"startTime":"0","endTime":"0","summary":"Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology's clinically-validated LYT-200 for myeloid malignancies, and Seaport Therapeutics' advancing clinical-stage pipeline for neuropsychiatric disorders. PureTech level cash, cash equivalents and short-term investments of $277.1 million and Consolidated cash, cash equivalents and short-term investments of $277.3 million as of December 31, 2025; Operational runway at least through the end of 2028, inclusive of the Company's expected participation in Founded Entity fundraisings. As of March 31, 2026, PureTech level cash and cash equivalents were $248.1 million. Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST. Members of the PureTech management team will host a conference call at 9:00am EDT / 2:00pm BST today, April 29, 2026, to discuss these results. A li","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATS","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630891955","title":"ATS Corporation price target raised to C$51 from C$48 at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2630891955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630891955?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:41","pubTimestamp":1777390864,"startTime":"0","endTime":"0","summary":"Scotiabank raised the firm’s price target on ATS Corporation (ATS) to C$51 from C$48 and keeps an Outperform rating on the shares. Published first ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ats-corporation-price-target-raised-to-c51-from-c48-at-scotiabank-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ats-corporation-price-target-raised-to-c51-from-c48-at-scotiabank-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":115,"code":"91000000","status":"200"}]}}